Gannet BioChem and Re-Vana Therapeutics Enter Development and cGMP Supply Agreement to Support Ophthalmic Drug Delivery Program

Skip to Content News Archives Economy Defence Energy Oil & Gas Renewables Electric Vehicles Mining Commodities Agriculture Real Estate Mortgages Mortgage Rates Finance Banking Insurance Fintech Cryptocurrency Defence Work Wealth Smart Money Wealth Management Investor Personal Finance Family Finance Retirement Taxes High Net Worth FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials More Innovation Information Technology FP500 Podcasts Small Business Lives Told Tails Told Shopping Financial Post Store Obituaries Place a Notice Advertising Advertising With Us Advertising Solutions Postmedia Ad Manager Sponsorship Requests Classifieds Place a Classifieds ad Working Profile Settings My Subscriptions My Offers Newsletters Customer Service FAQ News Economy Energy Mining Real Estate Finance Defence Work Wealth Investor FP Comment Executive Women Puzzmo Newsletters Financial Times Business Essentials This advertisement has not loaded yet, but your article continues below.HomeGlobeNewswireThis section is The content in this section is supplied by GlobeNewswire for the purposes of distributing press releases on behalf of its clients. Postmedia has not reviewed the content. by GlobeNewswire Gannet BioChem and Re-Vana Therapeutics Enter Development and cGMP Supply Agreement to Support Ophthalmic Drug Delivery ProgramAuthor of the article:The agreement supports EyeLief® combination drug-device product development in anticipation of a future clinical program, with polymer supply also supporting OcuLief® and non-ocular applicationsTHIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLYSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.SUBSCRIBE TO UNLOCK MORE ARTICLESSubscribe now to read the latest news in your city and across Canada.Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.Daily content from Financial Times, the world's leading global business publication.Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.Daily puzzles, including the New York Times Crossword.REGISTER / SIGN IN TO UNLOCK MORE ARTICLESCreate an account or sign in to continue with your reading experience.Access articles from across Canada with one account.Share your thoughts and join the conversation in the comments.Enjoy additional articles per month.Get email updates from your favourite authors.THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.Create an account or sign in to continue with your reading experience.Access articles from across Canada with one accountShare your thoughts and join the conversation in the commentsEnjoy additional articles per monthGet email updates from your favourite authorsSign In or Create an AccountHUNTSVILLE, Ala., Oct. 27, 2026 (GLOBE NEWSWIRE) — Gannet BioChem, a specialized contract development and manufacturing organization (CDMO) focused on activated polymers and bioconjugation, and Re-Vana Therapeutics, a biotechnology company developing sustained-release therapeutics and drug delivery technologies, today announced a development and cGMP supply agreement to support the advancement of Re-Vana’s proprietary biodegradable polymer platforms.This advertisement has not loaded yet, but your article continues below.The agreement represents an important step in Re-Vana’s progression toward clinical development. Through the collaboration, the companies will develop and scale manufacturing processes for Re-Vana’s proprietary polymers and establish supply under current Good Manufacturing Practice (cGMP).Get the latest headlines, breaking news and columns.By signing up you consent to receive the above newsletter from Postmedia Network Inc.A welcome email is on its way. If you don't see it, please check your junk folder.The next issue of Top Stories will soon be in your inbox.We encountered an issue signing you up. Please try againRe-Vana’s EyeLief® technology is a preformed, photo-crosslinked, biodegradable implant designed to provide sustained delivery of therapeutics for serious retinal diseases. By extending drug delivery, Re-Vana aims to reduce the frequency of injections into the eye while helping patients preserve their vision.The cGMP-manufactured polymers will also support development of Re-Vana’s OcuLief® platform, which forms a sustained-release implant through photo-crosslinking following injection, and the company’s expanding non-ocular programs. Establishing a manufacturing foundation across these programs is intended to support consistent material quality, reproducibility and scale-up as Re-Vana advances its internal pipeline and strategic collaborations.This advertisement has not loaded yet, but your article continues below.“This agreement marks an important development milestone for Re-Vana as we advance our EyeLief® combination drug-device product development in anticipation of a future clinical program,” said Patrick H. Ruane, Ph.D., Chief Operating Officer of Re-Vana Therapeutics. “Establishing a scalable cGMP supply of our proprietary polymers is a key part of that progression. These materials will also support OcuLief® and our non-ocular programs, extending the value of this collaboration across our portfolio. Gannet BioChem’s expertise in polymer chemistry, process development and cGMP manufacturing makes them a valuable partner as we translate our platform capabilities into products for patients.”The collaboration combines Re-Vana’s proprietary macromer chemistry and sustained-release platform expertise with Gannet’s capabilities in polyethylene glycol (PEG) chemistry, process development, analytical characterization and cGMP manufacturing.“Innovative drug delivery technologies depend on the quality and consistency of the materials behind them,” said Nicholas Shackley, Chief Executive Officer of Gannet BioChem. “We’re pleased to collaborate with Re-Vana, combining our specialized polymer expertise with their innovative approach to ophthalmic drug delivery to support the advancement of technologies that could make a meaningful difference for patients.”This advertisement has not loaded yet.This advertisement has not loaded yet, but your article continues below.Both Gannet BioChem and Re-Vana will attend the Partnership Opportunities in Drug Delivery (PODD) Conference, October 29–30, 2026, in Boston, Massachusetts. As an exhibiting sponsor, Gannet looks forward to connecting with industry leaders to discuss how its activated polymer technologies and manufacturing capabilities can support next-generation drug delivery applications. Attendees can schedule a meeting with the Gannet team. Re-Vana will also present at PODD.Gannet BioChem is a leading specialty CDMO focused on the development, scale-up, and manufacturing of activated polymers, including polyethylene glycol (PEG) reagents, which are critical components used in advanced biopharmaceutical, therapeutic, and medical device products. With more than 30 years of industry expertise, the company provides high-quality activated polymers, including PEG reagents, and related services to support customers from early development through commercialization. With a highly experienced scientific team, rigorous quality systems, and a strong track record supporting FDA, EU, and other regulatory agency approvals, Gannet BioChem delivers reliable, scalable solutions to meet the evolving needs of the global biopharmaceutical industry. For additional information, please visit GannetBioChem.com or follow us on LinkedIn.This advertisement has not loaded yet, but your article continues below.About Re-Vana TherapeuticsRe-Vana Therapeutics Ltd, founded in 2016 as a spin-out from Queen’s University Belfast, is an ocular therapeutics and oncology drug delivery company based in Belfast, Northern Ireland, and a wholly owned subsidiary of Re-Vana Holding, Inc., Tampa, Florida.Re-Vana is venture-backed by leading U.S. ophthalmic investors, including Visionary Ventures, ExSight Ventures and InFocus Capital Partners, as well as U.K. investors including QUBIS, Techstart Ventures, Invest Northern Ireland and Clarendon Fund Managers. The company is advancing sustained-release technologies designed to address unmet needs in the treatment of serious eye diseases and oncology. Learn more at www.revanatx.com.Media ContactsGannet BioChem – Gabbie Burbanks, Marketinggburbanks@gannetbiochem.comRe-Vana Therapeutics – Daphne Doucet, Chief of Staffd.doucet@revanatx.comThis advertisement has not loaded yet.Notice for the Postmedia NetworkThis website uses cookies to personalize your content (including ads), and allows us to analyze our traffic. Read more about cookies here. By continuing to use our site, you agree to our Terms of Use and Privacy Policy.